Hematology Advisor

Latest

“Good-Risk” Group of Patients With Myeloma Saw Better Outcomes

Monjuvi Approved for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Two Trials Evaluate CAR-T Cell Therapy for Relapsed/Refractory Hodgkin Lymphoma

Venous Thromboembolism Events With COVID-19 in an Intensive Care Unit

DEA Warns of Extortion Scam Targeting Healthcare Providers

Survivors of Adolescent, Young Adult ALL May Suffer Late Effects

Deep Vein Thrombosis Detection in Patients With Hemophilia A Undergoing Total Knee Arthroplasty

Genomic Analysis to Determine Patient Survival in Newly Diagnosed Multiple Myeloma

Identifying Risk Factors for Invasive Fungal Infection in Ibrutinib-Treated CLL Patients

COVID-19 Vaccine Candidate Provides Protection in Animal Challenge Study

Respiratory Sampling Strategies for Detecting SARS-CoV-2 Compared

Safety, Efficacy of Addition of Daratumumab to Treatment in Relapsed or Refractory Multiple Myeloma

High Molecular Response With Lenalidomide, Rituximab in Untreated Follicular Lymphoma

Thalassemias

Treatment Considerations for Thalassemia in the Emergency Department

Antoine N. Saliba, MD, and colleagues summarized current literature surrounding the frequent complications that bring patients with thalassemia into the ED.

Myeloma

New Class of Drug Appears to Extend Survival in Patients With Triple-Refractory Multiple Myeloma

Oncopeptides will seek accelerated approval from the FDA after melflufen demonstrates a manageable safety profile.

General Hematology

Prepare to E-Prescribe Controlled Substances

Beginning January 1, 2021, a federal law called the Every Prescription Conveyed Securely Act takes effect requiring that prescriptions for controlled substances covered under Medicare be prescribed electronically.

Anemia

ASH 2020 Guidelines: Management of Acute and Chronic Pain in Sickle Cell Disease

The American Society of Hematology released their evidence-based 2020 guidelines on the management of acute and chronic pain in sickle cell disease.